Cannabis Bioscience International Holdings Inc. recently released its annual report for the fiscal year ending May 31, 2025. The company, headquartered in Houston, Texas, focuses on educational systems related to medical cannabis in the United States and Latin America, and globally through online platforms. It operates through its divisions: Alpha Research Institute, Pharmacology University, and its CBD Business. The company reported its financial results, stating that its operations include conducting clinical trials, providing cannabis-related education, and selling CBD products. However, there is substantial doubt about the company's ability to continue as a going concern unless adequate capital is secured. The company aims to enhance its revenue and profitability by introducing advanced nanotechnology products, which are expected to improve solubility, stability, targeted delivery, and the overall bioavailability of therapeutic compounds. No specific figures for sales, net income, or earnings per share were provided in the report.